Real World Study of Linperlisib for Lymphoma Treatment

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Focus on the Lymphoma Including B/T-cell Lymphoma

Interventions

DRUG

Linperlisib

80 mg, qd

Trial Locations (2)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital, Tianjin

All Listed Sponsors

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

lead

Ruijin Hospital

OTHER

NCT05863871 - Real World Study of Linperlisib for Lymphoma Treatment | Biotech Hunter | Biotech Hunter